Sage Therapeutics Announces Second Quarter 2023 Financial Re

ZURZUVAE™ approved as first-and-only oral treatment specifically indicated for adults with postpartum depression and on-track for planned launch in the fourth quarter of 2023 shortly after DEA...

Related Keywords

Barry Greene , Us Drug Enforcement Administration , Exchange Commission , Biogen Inc , Drug Administration , Early Development , Sage Therapeutics Inc , National Pregnancy Registry For Antidepressants , Nasdaq , European Medicines Agency , Sage Therapeutics , Chief Executive Officer , Complete Response Letter , Enforcement Administration , New Drug Application , Fast Track Designation , Orphan Drug Designation , Biogen Collaboration , License Agreement , Private Securities Litigation Reform Act , Consolidated Statements , Months Ended June , National Pregnancy Registry , Full Prescribing Information , Medication Guide , Controlled Substances , Markets ,